Greenwich LifeSciences, Inc.
Symbol: GLSI (NASDAQ)
11.79
▲ (3.51%) 0.400
Company Description:
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Key Stats
- Today's Open: $11.19
- Today's High: $11.79
- Today's Low: $11.19
- Today's Volume: 303
- Yesterday Close: $11.39
- Yesterday High: $13
- Yesterday Low: $11.1337
- Yesterday Volume: 348.06K
- Last Min Volume: 40
- Last Min High: $11.79
- Last Min Low: $11.79
- Last Min VWAP: $11.79
Company Profile
- Name: Greenwich LifeSciences, Inc.
- Website: https://www.greenwichlifesciences.com
- Listed Date: 2020-09-25
- Location: STAFFORD, TX
- Market Status: Active
- CIK Number: 0001799788
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $155.25M
- Round Lot: 100
- Outstanding Shares: 13.63M
- Asset Type: CS
RECENT FILINGS FOR GLSI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | 10-Q | View |
| 2025-07-24 | 8-K | View |
| 2025-05-20 | 10-Q | View |
| 2025-05-15 | NT 10-Q | View |
| 2025-04-29 | 4 | View |
| 2025-04-22 | 4 | View |
| 2025-04-15 | 10-K | View |
| 2025-04-08 | 4 | View |
| 2025-04-07 | 4 | View |
| 2025-03-31 | NT 10-K | View |
| 2025-01-13 | 4 | View |
| 2025-01-08 | 4 | View |
| 2025-01-07 | 4 | View |
| 2025-01-06 | 4 | View |
| 2025-01-03 | 4 | View |
| 2025-01-02 | 4 | View |
| 2024-12-27 | 4 | View |
| 2024-12-27 | 4 | View |
| 2024-12-27 | 4 | View |
| 2024-12-27 | 4 | View |
Latest News on GLSI